Thomas Schurpf

Thomas Schurpf

Company: Scholar Rock

Job title: Associate Director


Inhibition of TGFβ1 Activation with SRK-181 to Overcome Primary Resistance to Checkpoint Inhibition Therapy 12:30 pm

• Retrospective analyses of clinical tumor samples have identified the TGFβ pathway as a potential contributor to primary resistance to checkpoint inhibition therapy • Selective inhibition of TGFβ1 activation with SRK-181 induces profound combination treatment effects with anti–PD-1 on tumor growth in checkpoint inhibition therapy-resistant tumors • TGFβ1 isoform specificity of SRK-181 results in improved…Read more

day: Day Two

Panel Discussion: Debating the Best Approach to Target TGF-ß 10:45 am

• Which TGF-ß isoform to target to maximize therapeutic potential in IO and minimize adverse risk • Combination approaches vs monotherapy? • Is there one therapeutic approach with greater potential than others?Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.